Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the effect of Epoetin Alfa (Procrit) on the
change in hemoglobin (red blood cell count) in anemic kidney transplant recipients. The
investigators hypothesize that epoetin alfa will raise hemoglobin.